Neupro Related Published Studies
Well-designed clinical trials related to Neupro (Rotigotine)
Transdermal rotigotine in advanced Parkinson's disease: a randomized,
double-blind, placebo-controlled trial. [2014]
Rotigotine vs ropinirole in advanced stage Parkinson's disease: a double-blind
study. [2014]
Efficacy and safety of rotigotine in Japanese patients with restless legs
syndrome: a phase 3, multicenter, randomized, placebo-controlled, double-blind,
parallel-group study. [2013]
Drug safety evaluation of rotigotine. [2012]
Rotigotine improves restless legs syndrome: a 6-month randomized, double-blind,
placebo-controlled trial in the United States. [2010]
Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's
disease: a double-blind, double-dummy, randomised controlled trial. [2007]
Transdermal rotigotine: double-blind, placebo-controlled trial in Parkinson
disease. [2007]
Advanced Parkinson disease treated with rotigotine transdermal system: PREFER
Study. [2007]
Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson
disease. [2007]
Well-designed clinical trials possibly related to Neupro (Rotigotine)
Emerging analgesic drugs for Parkinson's disease. [2012]
Tolerability and safety of ropinirole versus other dopamine agonists and levodopa
in the treatment of Parkinson's disease: meta-analysis of randomized controlled
trials. [2010]
Impact of newer pharmacological treatments on quality of life in patients with Parkinson's disease. [2008]
Transdermal dopaminergic D(2) receptor agonist therapy in Parkinson's disease
with N-0923 TDS: a double-blind, placebo-controlled study. [2001]
Other research related to Neupro (Rotigotine)
Rotigotine in the treatment of primary restless legs syndrome: A meta-analysis of
randomized placebo-controlled trials. [2015]
Comparison of the bioavailability and adhesiveness of different rotigotine
transdermal patch formulations. [2013]
Outcomes of rotigotine clinical trials: effects on motor and nonmotor symptoms of
Parkinson's disease. [2013]
Rotigotine transdermal patch in Parkinson's disease: a systematic review and
meta-analysis. [2013]
Adenosine A2A receptor antagonist istradefylline reduces daily OFF time in
Parkinson's disease. [2013]
Rotigotine and specific non-motor symptoms of Parkinson's disease: post hoc
analysis of RECOVER. [2013]
Rotigotine for restless legs syndrome. [2009]
High doses of rotigotine transdermal patch: results of an open-label,
dose-escalation trial in patients with advanced-stage, idiopathic Parkinson
disease. [2009]
Lack of pharmacokinetic interactions between transdermal rotigotine and oral
levodopa/carbidopa. [2009]
Absorption, disposition, metabolic fate, and elimination of the dopamine agonist
rotigotine in man: administration by intravenous infusion or transdermal
delivery. [2009]
Thorough QT/QTc study in patients with advanced Parkinson's disease: cardiac
safety of rotigotine. [2008]
Rotigotine transdermal patch in early Parkinson's disease: a randomized,
double-blind, controlled study versus placebo and ropinirole. [2007]
Rotigotine: a novel dopamine agonist for the transdermal treatment of Parkinson's
disease. [2006]
Other possibly related research studies
ADMET considerations for restless leg syndrome drug treatments. [2012]
The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments
for the motor symptoms of Parkinson's disease. [2011]
Randomized trials of dopamine agonists in restless legs syndrome: a systematic
review, quality assessment, and meta-analysis. [2010]
Associations between severity of motor function and nonmotor symptoms in
Parkinson's disease: a post hoc analysis of the RECOVER Study. [2014]
Relation of the International Restless Legs Syndrome Study Group rating scale
with the Clinical Global Impression severity scale, the restless legs syndrome
6-item questionnaire, and the restless legs syndrome-quality of life
questionnaire. [2013]
The effect of dopamine agonists on cognitive functions in non-demented early-mild
Parkinson's disease patients. [2013]
Meta-analysis of the efficacy and safety of long-acting non-ergot dopamine
agonists in Parkinson's disease. [2014]
Long-acting versus standard non-ergot dopamine agonists in Parkinson's disease: a
meta-analysis of randomized controlled trials. [2014]
|